Figure 8.
B-mode ultrasound (US) imaging of DU-145 tumor xenografts treated with microbubble/US-guided Ad.mda-7 and therapy resistant DU-Bcl-xL tumor xenografts treated with microbubble/US-guided cancer terminator virus (CTV). Subcutaneous tumor xenografts from DU-145 and DU-Bcl-xL cells were established in athymic nude mice in both right and left flanks and only tumors on the right side were sonoporated following tail-vein injection of the indicated microbubble/Ad complexes during a course of 4 weeks. Tumor volumes were determined by measuring twice a week the tumors with either a caliper or by US measurements of the tumor axes. (a) Ultrasound image and measurement of a DU-145 tumor before treatment with Ad.mda-7/microbubble complexes and US. (b) US image and measurement of the same DU-145 tumor 2 weeks following treatments with Ad.mda-7/microbubble complexes and US. (c) US image and measurement of the same DU-145 tumor 4 weeks following treatments with Ad.mda-7/microbubble complexes and US. (d) US image and measurement of a DU-Bcl-xL tumor before treatment with CTV/microbubble complexes and US. (e) US image and measurement of the same DU-Bcl-xL tumor 2 weeks following treatments with the CTV/microbubble complexes and US. (f) US image and measurement of the same DU-Bcl-xL tumor 4 weeks following treatments with CTV/microbubble complexes and US. Complete eradication of the DU-Bcl-xL tumor occurs 4 weeks after initiating the therapeutic treatment protocol. Ad, adenovirus; GFP, green fluorescent protein.